News & Updates

Among women with obesity and atypical hyperplasia or low-risk endometrial cancer, weight loss during conservative management with intrauterine progestin improves treatment outcomes, according to a study.

Among healthy individuals, a fasting plasma glucose (FPG) concentration within the range of 90–99 mg/dL increases the risk of type 2 diabetes, a new Japan study has found.

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.

Individuals with long-term metabolic syndrome are at increased risk of developing gastrointestinal cancer overall, including colorectal and pancreatic cancers and hepatocellular carcinoma, with the risk increase independent of genetic predisposition, a study has found.

Ertugliflozin, a novel sodium-glucose cotransporter inhibitor, helps reduce glycated haemoglobin (HbA1c), body weight, and fasting plasma glucose (FPG) in patients with type 2 diabetes, reports a recent meta-analysis.

Type 2 diabetes (T2D) patients who are taking multiple medications together are at heightened risk of bone fractures, a study has found.

Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.

A total diet replacement programme produces greater weight loss among people with obesity as compared with support from a practice nurse, with the benefit persisting to at least 3 years, a study has found.